Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Eun
Hee Han, Yong
Pil Hwang, Hyung
Gyun Kim, Jin
Hee Park, Tae
Cheon Jeong & Hye
Gwang Jeong. (2010) Upregulation of Cyclooxygenase-2 by 4-Nonylphenol is Mediated Through the Cyclic Amp Response Element Activation Pathway. Journal of Toxicology and Environmental Health, Part A 73:21-22, pages 1451-1464.
Read now
Read now
Articles from other publishers (15)
Shingo Maeda, Kohei Murakami, Akiko Inoue, Tomohiro Yonezawa & Naoaki Matsuki. (2019) CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer. Cancer Immunology Research 7:7, pages 1175-1187.
Crossref
Crossref
Mei-Chih Chen, Shih-Lan Hsu, Ho Lin & Tsung-Ying Yang. (2014) Retinoic acid and cancer treatment. BioMedicine 4:4.
Crossref
Crossref
D. W. Knapp, J. A. Ramos-Vara, G. E. Moore, D. Dhawan, P. L. Bonney & K. E. Young. (2014) Urinary Bladder Cancer in Dogs, a Naturally Occurring Model for Cancer Biology and Drug Development. ILAR Journal 55:1, pages 100-118.
Crossref
Crossref
B. W. Davis & E. A. Ostrander. (2014) Domestic Dogs and Cancer Research: A Breed-Based Genomics Approach. ILAR Journal 55:1, pages 59-68.
Crossref
Crossref
Maria Cekanova, Md. Jashim Uddin, Joseph W. Bartges, Amanda Callens, Alfred M. Legendre, Kusum Rathore, Laura Wright, Amanda Carter & Lawrence J. Marnett. (2013)
Molecular Imaging of Cyclooxygenase-2 in Canine Transitional Cell Carcinomas
In Vitro
and
In Vivo
. Cancer Prevention Research 6:5, pages 466-476.
Crossref
Crossref
Amanda L. Blackburn, Allyson C. Berent, Chick W. Weisse & Dorothy C. Brown. (2013) Evaluation of outcome following urethral stent placement for the treatment of obstructive carcinoma of the urethra in dogs: 42 cases (2004–2008). Journal of the American Veterinary Medical Association 242:1, pages 59-68.
Crossref
Crossref
Ruth L. Vinall, Michael S. Kent & Ralph W. deVere White. (2012) Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. American Journal of Veterinary Research 73:10, pages 1626-1633.
Crossref
Crossref
Joao Felipe de Brito Galvao, William C. Kisseberth, Sridhar Murahari, Saikaew Sutayatram, Dennis J. Chew & Nongnuch Inpanbutr. (2012) Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines. American Journal of Veterinary Research 73:8, pages 1262-1272.
Crossref
Crossref
Dimitrios Iliopoulos, Asaf Rotem & Kevin Struhl. (2011) Inhibition of miR-193a Expression by Max and RXRα Activates K-Ras and PLAU to Mediate Distinct Aspects of Cellular Transformation. Cancer Research 71:15, pages 5144-5153.
Crossref
Crossref
Laura Marconato, Eric Zini, Donna Lindner, Lisa Suslak-Brown, Victoria Nelson & Ann K. Jeglum. (2011) Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder. Journal of the American Veterinary Medical Association 238:8, pages 1004-1010.
Crossref
Crossref
G. Borzacchiello, V. Russo & M. Russo. (2007) Immunohistochemical Expression of Cyclooxygenase-2 in Canine Ovarian Carcinomas. Journal of Veterinary Medicine Series A 54:5, pages 247-249.
Crossref
Crossref
William A. LaFramboise, Kelly L. Bombach, Andrew R. Pogozelski, Ryan F. Cullen, Noah Muha, James Lyons-Weiler, Scott J. Spear, Rajiv J. Dhir, Robert D. Guthrie & James A. Magovern. (2012) Hepatic Gene Expression Response to Acute Indomethacin Exposure. Molecular Diagnosis & Therapy 10:3, pages 187-196.
Crossref
Crossref
Sarki A AbdulkadirJongchan Kim. (2005) Genetically engineered murine models of prostate cancer: insights into mechanisms of tumorigenesis and potential utility. Future Oncology 1:3, pages 351-360.
Crossref
Crossref
Ahmed S. Mehanna. (2003) NSAIDs: Chemistry and Pharmacological Actions. American Journal of Pharmaceutical Education 67:2, pages 63.
Crossref
Crossref
Mark A. Moyad. (2003) Bladder cancer recurrence: Part II. What do I tell my patients about lifestyle changes and dietary supplements?. Current Opinion in Urology 13:5, pages 379-383.
Crossref
Crossref